Oroxylin A Reduces Vasoconstriction in Rat Aortic Rings through Promoting NO Production and NOS Protein Expression via Estrogen Receptor Signal Pathway.
Jingtian QuFang LiuXuezhu ZhangJialong WangPublished in: Evidence-based complementary and alternative medicine : eCAM (2020)
Oroxylin A, a flavonoid, is naturally produced in many medicinal plants. Our previous study identified it as a phytoestrogen. Based on this, the present study investigated its vasoconstriction reducing effects and whether the action was mediated by the estrogen receptor (ER) signal pathway. Long-term in vitro treatment with oroxylin A reduced Ach-induced vasorelaxation and NE-mediated or KCl-mediated contractile responses in rat aortic rings. These effects were interfered by an ER inhibitor ICI 182,780. Rat cardiac microvascular endothelial cells (CMECs) and aortic vascular smooth muscle cells (VSMCs) were used to study the possible underlying mechanisms. Oroxylin A activated the ER signal pathway. In CMECs, it increased NO production and eNOS protein expression. In VSMCs, it promoted NO production and iNOS protein expression. These effects were also inhibited by ICI 182,780. Besides, oroxylin A stimulated ERα and ERβ protein expression in CMECs and VSMCs. All these findings suggest that the ER signal pathway takes part in the vasoconstriction reducing effects of oroxylin A.
Keyphrases
- estrogen receptor
- vascular smooth muscle cells
- left ventricular
- endoplasmic reticulum
- breast cancer cells
- aortic valve
- pulmonary artery
- angiotensin ii
- nitric oxide synthase
- heart failure
- nitric oxide
- coronary artery
- signaling pathway
- pi k akt
- pulmonary hypertension
- mass spectrometry
- stress induced
- high resolution
- drug induced
- smooth muscle
- high speed